Veru Inc. (VERU)
VERU Stock Price Chart
Explore Veru Inc. interactive price chart. Choose custom timeframes to analyze VERU price movements and trends.
VERU Company Profile
Discover essential business fundamentals and corporate details for Veru Inc. (VERU) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Feb 1999
Employees
210.00
Website
https://www.verupharma.comCEO
Mitchell S. Steiner
Description
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
VERU Financial Timeline
Browse a chronological timeline of Veru Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.34, while revenue estimate is $1.70m.
Earnings released on 13 May 2026
EPS came in at -$0.13 surpassing the estimated -$0.31 by +58.06%.
Earnings released on 11 Feb 2026
EPS came in at -$0.26 surpassing the estimated -$0.47 by +44.68%.
Earnings released on 17 Dec 2025
EPS came in at -$0.60 falling short of the estimated -$0.37 by -64.38%, while revenue for the quarter reached $247.06k .
Earnings released on 12 Aug 2025
EPS came in at -$0.50 surpassing the estimated -$0.55 by +9.09%.
Stock split effective on 11 Aug 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 13 Feb 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.
Earnings released on 16 Dec 2024
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $6.66m , beating expectations by +86.98%.
Earnings released on 8 Aug 2024
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%, while revenue for the quarter reached $3.95m , beating expectations by +11.06%.
Earnings released on 8 May 2024
EPS came in at -$0.07 falling short of the estimated -$0.05 by -40.00%, while revenue for the quarter reached $4.14m , beating expectations by +37.84%.
Earnings released on 1 Apr 2024
EPS came in at -$0.82 surpassing the estimated -$2.35 by +65.11%, while revenue for the quarter reached $3.86m , missing expectations by -2.23%.
Earnings released on 8 Dec 2023
EPS came in at -$0.16 surpassing the estimated -$0.20 by +20.00%, while revenue for the quarter reached $3.86m , missing expectations by -2.23%.
Earnings released on 10 Aug 2023
EPS came in at -$0.13 surpassing the estimated -$0.20 by +35.00%, while revenue for the quarter reached $3.34m , missing expectations by -15.41%.
Earnings released on 11 May 2023
EPS came in at -$0.44 falling short of the estimated -$0.33 by -33.33%, while revenue for the quarter reached $6.59m , beating expectations by +52.45%.
Earnings released on 9 Feb 2023
EPS came in at -$0.46 falling short of the estimated -$0.38 by -21.05%, while revenue for the quarter reached $2.51m , missing expectations by -50.50%.
Earnings released on 5 Dec 2022
EPS came in at -$0.51 falling short of the estimated -$0.29 by -75.86%, while revenue for the quarter reached $2.59m , missing expectations by -77.59%.
Earnings released on 11 Aug 2022
EPS came in at -$0.28 falling short of the estimated -$0.18 by -55.56%, while revenue for the quarter reached $9.60m , missing expectations by -42.39%.
Earnings released on 12 May 2022
EPS came in at -$0.18 falling short of the estimated -$0.16 by -12.50%, while revenue for the quarter reached $13.03m , beating expectations by +6.72%.
Earnings released on 9 Feb 2022
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%, while revenue for the quarter reached $14.14m , beating expectations by +2.12%.
Earnings released on 2 Dec 2021
EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%, while revenue for the quarter reached $15.65m , beating expectations by +20.36%.
Earnings released on 12 Aug 2021
EPS came in at -$0.03 surpassing the estimated -$0.06 by +50.00%, while revenue for the quarter reached $17.66m , beating expectations by +25.22%.
VERU Stock Performance
Access detailed VERU performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
